Novartis (NVS) announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer remained progression-free for four or more years following treatment with Kisqali plus endocrine therapy. Results were from a pooled, post-hoc exploratory analysis of first-line patients in the MONALEESA trials and will be presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025. Metastatic breast cancer is cancer that has spread beyond the breasts to other parts of the body. Long-term progression-free survival benefit with Kisqali was observed in patients regardless of their menopausal status and was achieved even in a proportion of patients with unfavorable prognostic factors. Patients had a median progression-free survival of 6.8 years. The median overall survival was not estimable. Kisqali has demonstrated statistically significant overall survival across all three Phase III MONALEESA trials2-12.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis upgraded to Overweight from Neutral at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports